CORPAY
22.6.2022 13:02:09 CEST | Business Wire | Press release
The Fédération Internationale de Natation (FINA) and Corpay, a FLEETCOR® (NYSE: FLT) brand and global leader in business payments, are today delighted to announce a multi-year collaboration that will see Corpay Cross-Border group provide their foreign exchange (FX) solutions to FINA. This new deal was announced on the occasion of the 19th FINA World Championships Budapest 2022, which is playing host to the leading aquatics athletes from across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005024/en/
FINA and the wider FINA Family will gain access to Corpay’s innovative foreign exchange solutions to help manage currency exposure for international payments. In addition, Corpay Cross-Border’s award-winning trading platform will enable FINA to manage global foreign exchange payments from one single point of access.
As the global governing body of six aquatic disciplines – Swimming, Water Polo, Diving, High Diving, Artistic Swimming and Open Water Swimming – FINA’s collaboration with Corpay Cross-Border will create valuable opportunities for the global aquatic’s community, event hosts and FINA partners providing international payments and foreign exchange solutions and capabilities.*
FINA President Captain Husain Al-Musallam expressed his confidence in the partnership with Corpay: “We are very excited to have Corpay Cross-Border join the FINA family at such an exciting time for the Federation. With more than seventy international events annually, this collaboration is certain to help drive financial efficiencies with the multiple foreign currency transactions we undertake with our event hosts, member federations and partners on an annual basis.”
Corpay Cross-Border President, Mark Frey continued “Corpay Cross-Border is very honoured to join the FINA family as their Official FX Payments Supplier. I am confident that FINA and the broader FINA Family will benefit from access to our comprehensive cross-border payments and FX risk management solutions, along with our payments experience gained within the world of sports.” “We look forward to helping them power their global payments and execute their plans to manage their currency risk for many years to come.”
About Corpay
Corpay is a global leader in business payments, helping companies of all sizes better track, manage and pay their expenses. Corpay provides customers with a comprehensive suite of online payment solutions including Bill Payment, AP Automation, Cross-Border Payments, Currency Risk Management, and Commercial Card Programs. As the largest commercial issuer of Mastercard in North America, Corpay handles over a billion transactions each year. Corpay is part of the FLEETCOR (NYSE: FLT) portfolio of brands. To learn more visit www.corpay.com
.
About International Swimming Federation/ Fédération Internationale de Natation
Founded in 1908, FINA is the global governing body for aquatics sports. FINA’s main objectives is to promote and encourage the development of Aquatics throughout the world, ensuring fair competition and universality in participation. Comprising 209 affiliated National Member Federations on six continents it is headquartered in the Olympic capital city of Lausanne (SUI). FINA and its aquatic disciplines are a pillar of the Olympic Movement and give a decisive contribution to the success of the Games. Five FINA disciplines currently feature on the quadrennial Olympic programme – Swimming, Water Polo, Diving, Artistic Swimming and Open Water Swimming.
1 “Corpay” (a Fleetcor (NYSE: FLT) brand) in this document primarily refers to the Cross-Border Division of Corpay https://payments.corpay.com/cross-border ; a full listing of the companies that are part of the Corpay brand is available here: https://payments.corpay.com/compliance .
* Subject to credit and compliance approval from the relevant Corpay company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
